¿Is COVID-19 a disease that affects the bone marrow? Experience in healthy donors of hematopoietic cells in a transplant center
Article Sidebar
Main Article Content
Abstract
Objective: to write and analyze the effect of SARS-CoV-2 virus infection on cell mobilization in hematopoietic stem cell donors who attended the hematopoietic stem cell transplant unit of a highly complex medical institution in Medellín, Colombia. Methods: an analytical retrospective cross-sectional study based on medical records of patients undergoing bone marrow transplantation between March 2020 and March 2021. Results: of 64 hematopoietic cell donors and recipients, 22.2 % of recipients with a positive history of donor infection had granulocyte engraftment failure compared with 9.1 % of recipients without this history; there was no difference in mortality rate. The median number of CD34 cells mobilized in the donor population with a history of infection was 5 437 965 [IQR 5 070 714 – 7 215 985], similar to donors without a history (Median of 5 976 773 [IQR 5 046 689 – 7 276 463]) without finding differences (p=0.28). Conclusions: It is not possible to determine that SARS-CoV-2 infection generates changes in cells that are mobilized from an otherwise healthy hematopoietic stem cell donor; based on the performed statistical analysis, we do not believe that the data will change if the study population is expanded, although more prospective studies are required in the future.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Creative Commons
License Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
You are free to:
Share - copy and redistribute the material in any medium or format.
Adapt - remix, transform, and build upon the material The licensor cannot revoke these freedoms as long as you follow the license terms.
• Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
• NonCommercial — You may not use the material for commercial purposes.
• ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
• No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
References
Wiggill TM, Mayne ES, Vaughan JL, Louw S. Overview of the Haematological Effects of COVID-19 Infection Adv Exp Med Biol. 2021;1321:163-172. DOI: https://doi.org/10.1007/978-3-030-59261-5_14
Yu F, Jia R, Tang Y, Liu J, Wei B. SARS-CoV-2 infection and stem cells: Interaction and intervention. Stem Cell Res. 2020;46:101859. DOI: https://doi.org/10.1016/j.scr.2020.101859
Pascutti MF, Erkelens MN, Nolte MA. Impact of Viral Infections on Hematopoiesis: From Beneficial to Detrimental Effects on Bone Marrow Output. Front Immunol Front Immunol. 2016;16;7:364 DOI: https://doi.org/10.3389/fimmu.2016.00364
Debuc B, Smadja DM. Is COVID-19 a New Hematologic Disease? Stem Cell Rev Rep. 2021;17(1):4-8. DOI: https://doi.org/10.1007/s12015-020-09987-4
Domínguez-Rojas J, Campano W, Tasayco J, Siu-Lam A, Ortega-Ocas C, Atamari-Anahui N. Thrombotic thrombocytopenic purpura associated with COVID-19 in a critically ill child: a Peruvian case report. Bol Méd Hosp Infant México. 2022;79(2):7012. DOI: https://doi.org/10.24875/BMHIM.21000061
Terpos E, Ntanasis‐Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, et al. Hematological findings and complications of COVID ‐19. Am J Hematol. 2020;95(7):834-47. DOI: https://doi.org/10.1002/ajh.25829
Lazarian G, Quinquenel A, Bellal M, Siavellis J, Jacquy C, Re D, et al. Autoimmune haemolytic anaemia associated with COVID‐19 infection. Br J Haematol. 2020;190(1):29-31. DOI: https://doi.org/10.1111/bjh.16794
Rosenzweig JD, McThenia SS, Kaicker S. SARS‐CoV‐2 infection in two pediatric patients with immune cytopenias: A single institution experience during the pandemic. Pediatr Blood Cancer [Internet]. Pediatr Blood Cancer. 2020;67(9):e28503. DOI: https://doi.org/10.1002/pbc.28503
Hernandez JM, Quarles R, Lakshmi S, Casanas B, Eatrides J, McCoy E, et al. Pancytopenia and Profound Neutropenia as a Sequela of Severe SARS-CoV-2 Infection (COVID-19) With Concern for Bone Marrow Involvement. Open Forum Infect Dis. 2021;8(2):ofab017. DOI: https://doi.org/10.1093/ofid/ofab017
Sharma A, Bhatt NS, St Martin A, Abid MB, Bloomquist J, Chemaly RF, et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol. 2021;8(3):e185-93. DOI: https://doi.org/10.1016/S2352-3026(20)30429-4
Ljungman P, de la Camara R, Mikulska M, Tridello G, Aguado B, Zahrani MA, et al. COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. Leukemia. 2021;35(10):2885-94. DOI: https://doi.org/10.1038/s41375-021-01302-5
Daudt LE, Corso MCM, Kerbauy MN, de Assis LH dos S, Rechenmacher C, Colturato I, et al. COVID-19 in HSCT recipients: a collaborative study of the Brazilian Society of Marrow Transplantation (SBTMO). Bone Marrow Transplant. 2022;57(3):453-9. DOI: https://doi.org/10.1038/s41409-021-01561-x